Header Logo

Paul Jeffrey

Concepts (84)

Back to Profile
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Medicaid
11
2019
334
2.650
 Why?
Medication Therapy Management
3
2018
20
1.590
 Why?
Analgesics, Opioid
4
2019
483
1.460
 Why?
Antiviral Agents
4
2018
313
1.460
 Why?
Pain
3
2019
396
1.230
 Why?
Practice Patterns, Physicians'
5
2019
687
1.060
 Why?
Hepatitis C
2
2016
143
0.920
 Why?
Hepatitis C, Chronic
2
2018
88
0.690
 Why?
Drug Utilization Review
2
2017
52
0.670
 Why?
Drug and Narcotic Control
2
2017
28
0.660
 Why?
Uridine Monophosphate
1
2018
8
0.610
 Why?
Fluorenes
1
2018
13
0.610
 Why?
Medication Adherence
2
2017
239
0.600
 Why?
Benzimidazoles
1
2018
56
0.580
 Why?
Psychotropic Drugs
1
2018
81
0.570
 Why?
Hydrocodone
1
2017
6
0.560
 Why?
Drug Prescriptions
1
2018
168
0.540
 Why?
Hepacivirus
1
2018
140
0.540
 Why?
Progesterone
1
2017
158
0.540
 Why?
United States
11
2019
7390
0.530
 Why?
Premature Birth
1
2017
108
0.510
 Why?
State Government
1
2014
28
0.450
 Why?
Prescription Drug Misuse
1
2014
20
0.450
 Why?
Retrospective Studies
7
2018
6071
0.420
 Why?
Health Services Accessibility
1
2016
521
0.370
 Why?
Mental Disorders
1
2018
717
0.370
 Why?
Opioid-Related Disorders
2
2014
456
0.340
 Why?
Drug Combinations
3
2019
147
0.320
 Why?
Drug Costs
2
2016
54
0.240
 Why?
Cost Savings
2
2016
52
0.240
 Why?
Young Adult
4
2019
4267
0.240
 Why?
Adult
6
2019
15669
0.240
 Why?
Adolescent
4
2019
5824
0.230
 Why?
Cost-Benefit Analysis
2
2017
297
0.230
 Why?
Insurance, Pharmaceutical Services
2
2014
19
0.230
 Why?
Program Evaluation
2
2018
470
0.220
 Why?
Pharmacists
2
2016
122
0.220
 Why?
Female
7
2019
30705
0.210
 Why?
Humans
11
2019
59360
0.200
 Why?
Massachusetts
2
2018
2002
0.190
 Why?
Middle Aged
5
2019
16317
0.190
 Why?
Sofosbuvir
2
2018
18
0.190
 Why?
Male
6
2019
27739
0.180
 Why?
Cohort Studies
2
2017
2374
0.180
 Why?
Treatment Outcome
3
2016
5284
0.170
 Why?
Chloride Channel Agonists
1
2019
3
0.170
 Why?
Aminophenols
1
2019
4
0.170
 Why?
Benzodioxoles
1
2019
13
0.160
 Why?
Aminopyridines
1
2019
31
0.160
 Why?
Quinolones
1
2019
27
0.160
 Why?
Sustained Virologic Response
1
2018
10
0.150
 Why?
Cystic Fibrosis
1
2019
110
0.150
 Why?
Ribavirin
1
2018
24
0.150
 Why?
Polypharmacy
1
2018
61
0.150
 Why?
Treatment Failure
1
2018
185
0.150
 Why?
Hydroxyprogesterones
1
2017
6
0.140
 Why?
Insurance, Health, Reimbursement
1
2017
42
0.140
 Why?
Viral Load
1
2018
220
0.140
 Why?
Controlled Substances
1
2017
5
0.140
 Why?
Dose-Response Relationship, Drug
1
2019
806
0.140
 Why?
RNA, Viral
1
2018
259
0.140
 Why?
Drug Therapy, Combination
1
2018
452
0.140
 Why?
Gestational Age
1
2017
178
0.140
 Why?
Psychiatry
1
2018
114
0.130
 Why?
Genotype
1
2018
617
0.130
 Why?
Insurance Claim Review
1
2016
72
0.130
 Why?
Evidence-Based Medicine
1
2018
442
0.130
 Why?
Pregnancy Outcome
1
2017
181
0.130
 Why?
Prescription Drug Diversion
1
2014
7
0.110
 Why?
Lung
1
2019
919
0.110
 Why?
Government Regulation
1
2014
40
0.110
 Why?
Drug Interactions
1
2014
115
0.110
 Why?
Managed Care Programs
1
2014
88
0.110
 Why?
Interdisciplinary Communication
1
2014
103
0.110
 Why?
Physician's Role
1
2014
120
0.100
 Why?
Cooperative Behavior
1
2014
210
0.100
 Why?
Health Policy
1
2014
176
0.100
 Why?
Child
2
2019
4174
0.100
 Why?
Pregnancy
1
2017
2202
0.090
 Why?
Time Factors
1
2014
3617
0.070
 Why?
Aged
1
2018
13416
0.050
 Why?
Cystic Fibrosis Transmembrane Conductance Regulator
1
2019
74
0.040
 Why?
Ambulatory Care
1
2017
300
0.030
 Why?
Mutation
1
2019
2456
0.020
 Why?
Jeffrey's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (84)
Explore
_
Co-Authors (5)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_